Holen Sie sich die Stockscreener-App
5.76
4.00%
-0.24
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Dimensional Fund Advisors LP Buys 372,196 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates - simplywall.st
Wells Fargo & Company MN Acquires 11,427 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Canada
MetLife Investment Management LLC Purchases 2,776 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com Australia
Kura Oncology to Participate in Bank of America Securities Healt - GuruFocus
KURA Stock Set for Competitive Landscape in Menin Inhibitor Mark - GuruFocus
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - The Manila Times
Kura Oncology CEO Sets Stage for Major Updates at BofA Healthcare Conference Next Week - Stock Titan
Kura Oncology (NASDAQ:KURA) Cut to Hold at StockNews.com - Defense World
FY2026 EPS Estimates for Kura Oncology Increased by Analyst - Defense World
Barclays Cuts Kura Oncology (NASDAQ:KURA) Price Target to $11.00 - Defense World
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap Down Following Weak Earnings - Defense World
Kura Oncology Inc (KURA)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology (KURA) Grants Inducement Stock Options to New Empl - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Barclays Adjusts Price Target for Kura Oncology (KURA) Following Q1 Update | KURA Stock News - GuruFocus
Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances with Key NDA Submission - TipRanks
Kura Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kura Oncology: Q1 Earnings Snapshot - MySA
Kura Oncology Q1 2025 Earnings: Revenue Surges to $14.1M, EPS Ma - GuruFocus
Kura Oncology Inc earnings missed by $0.04, revenue topped estimates - Investing.com Canada
Kura Oncology Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Kura Oncology Q1 2025 reveals revenue boost By Investing.com - Investing.com South Africa
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology Reports First Quarter 2025 Financial Results - The Manila Times
Kura Oncology, Inc. SEC 10-Q Report - TradingView
Kura Oncology Achieves Major FDA Filing Milestone as Q1 Results Show $703M Cash Position - Stock Titan
Gastrointestinal Stromal Tumor Market Hits New High | Major Giants Novartis AG, Bayer AG, Kura Oncology - openPR.com
There is no doubt that Kura Oncology Inc (KURA) ticks all the boxes. - Sete News
JMP Securities Reaffirms “Market Outperform” Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology Inc [KURA] stock was sold by Hasnain Faheem at the price of US$0.18 million - knoxdaily.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Legal & General Group Plc - Defense World
Kura Oncology (KURA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kura Oncology stock holds $28 target from JMP on trial data - Investing.com Canada
Kura Oncology (NASDAQ:KURA) Receives Buy Rating from HC Wainwright - Defense World
Kura doses first subjects in trial of ziftomenib for advanced GIST - Yahoo Finance
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST - marketscreener.com
Kura Reports Dosing in Phase 1 Ziftomenib Combination Trial - marketscreener.com
Kura Oncology Announces First Patients Dosed in Phase 1 Combinat - GuruFocus
Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist - marketscreener.com
Kura Oncology (KURA) Advances Ziftomenib in GIST Clinical Trial - GuruFocus
Kura Oncology (KURA) Advances Ziftomenib in GIST Clinical Trial | KURA Stock News - GuruFocus
Kura Oncology Initiates Phase 1 Study of Ziftomenib Combined with Imatinib for Advanced GIST Patients After Imatinib Failure - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):